abstract |
the present invention relates to the medical use of specific glp-1 / glucagon receptor agonists in the prevention and / or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (nafld), more particularly non-alcoholic fatty liver (nafl) , non-alcoholic steatohepatitis (nash) and / or liver fibrosis associated with nafld. |